Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort

• Published in: Arthritis research & therapy 2018-08, Vol.20 (1), p.172-172, Article 172
• Main Authors: Dorais, Marc, Martel-Pelletier, Johanne, Raynauld, Jean-Pierre, Delorme, Philippe, Pelletier, Jean-Pierre
• Format: Article
• Language: English
• Subjects: Acetaminophen; Aged; Analgesics; Analgesics - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Antiarthritic agents; Arthritis; Arthroplasty, Replacement, Knee - statistics & numerical data; Body Mass Index; Care and treatment; Case-Control Studies; Chondroitin sulfate; Chondroitin Sulfates - therapeutic use; Development and progression; Female; Glucosamine - therapeutic use; Humans; Joint surgery; Knee; Knee replacement; Knee replacement arthroplasty; Male; Methods; Middle Aged; Narcotics; Nested case-control; NMR; NSAIDs; Nuclear magnetic resonance; Osteoarthritis; Osteoarthritis Initiative; Osteoarthritis, Knee - drug therapy; Osteoarthritis, Knee - surgery; Pain; Patient outcomes; Risk Factors
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-018-1656-2

The aim of this study was to measure the association between exposure to commonly used oral osteoarthritis (OA) therapies and relevant confounding risk factors on the occurrence of knee replacement (KR), using the Osteoarthritis Initiative (OAI) database. In this nested case-control design study, participants who had a KR after cohort entry were defined as "cases" and were matched with up to four controls for age, gender, income, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, Kellgren-Lawrence grade, and duration of follow up. Exposure to oral OA therapies (acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, narcotics, and glucosamine/chondroitin sulfate) was determined within the 3 years prior to the date of the KR. Conditional regression analyses were performed to estimate the association between KR and exposure to oral OA therapies and other potential confounding risk factors. A total of 218 participants who underwent a KR (cases) were matched to 540 controls. The median time to KR was 4.3 years among cases. The majority in both groups were Caucasian with mean age of 69 years and 61% were female. Numerically, cases were more exposed to acetaminophen, NSAIDs, and COX-2 inhibitors. Exposure to narcotics and glucosamine/chondroitin sulfate was relatively similar between cases and controls. No significant association was found between the occurrence of KR and exposure to any of the oral OA therapies within the 3 years prior to KR. A significantly higher occurrence of KR was found in Caucasian subjects (OR 1.84; 95% CI, 1.13-2.99; p = 0.015) and subjects with body mass index (BMI) ≥ 27 kg/m (OR 1.65; 95% CI, 1.06-2.58; p = 0.027). This study provides evidence that the main risk factors leading to KR are disease severity, symptoms and high BMI. Importantly, exposure to oral OA therapies was not associated with the occurrence of KR.